PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors and key findings from the Phase III PROpel study (11:03) Key findings from the Phase III MAGNITUDE and TALAPRO-2 studies (15:10) Summary of efficacy data with PARP inhibitors; toxicities (20:01) Key findings and conclusions from the Phase III AMPLITUDE study; future directions with PARP inhibitors (23:33) CME information and select publications